Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319456 | 0.88 | AR (0.60) | ARSLC22A12SLC6A4 | |
| SCHEMBL11189002 | 0.82 | AR (0.58) | ARPGRSLC22A12SLC6A4 | |
| SCHEMBL18189524 | 0.80 | IDH1 (0.50) | ARSLC22A12SLC6A4 | |
| SCHEMBL4857820 | 0.78 | AR (0.53) | ARPGRSLC6A4 | |
| SCHEMBL370151 | 0.77 | TTR (0.43) | — | |
| SCHEMBL1980445 | 0.77 | AR (0.51) | ARPGRSLC6A4 | |
| SCHEMBL28195741 | 0.76 | SLC22A12 (0.46) | ARPGRSLC22A12SLC6A4 | |
| SCHEMBL5343220 | 0.74 | ALDH1A1 (0.52) | ARPGR | |
| SCHEMBL5341215 | 0.74 | AR (0.46) | ARPGR | |
| SCHEMBL16319403 | 0.73 | EPAS1 (0.38) | ARSLC22A12SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | AR 392/4885PGR 3657/4885SLC22A12 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.